Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.

Clinical trial NCT07340619 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07340619
Sponsor: UNICANCER
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic (Stage IV) Melanoma

Start date: 2026-09-18
Primary completion: 2028-11-18
Enrollment: 51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.